Combination lurbinectedin and doxorubicin versus physician's choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trial
Santiago Ponce-Aix, Tudor–Eliade Ciuleanu, Alejandro Navarro et al. · The Lancet Respiratory Medicine · 2022
Cited by 128 works. doi:10.1016/s2213-2600(22)00309-5 Open-access PDF
Authors
- Santiago Ponce-Aix
- Tudor–Eliade Ciuleanu
- Alejandro Navarro
- Sophie Cousin
- Laura Bonanno
- Egbert Frederik Smit
- Alberto Chiappori
- Maria Eugenia Olmedo
- Ildikó Horváth
- Christian Grohé
- Anna F. Farago
- José Antonio López-Vilariño
- Martín Cullell-Young
- Noelia Vasco
- Javier Gómez
- Carmen Maria Kahatt
- Ali Hassan Zeaiter
- Enric Carcereny
- Jaromı́r Roubec
References
- The National Comprehensive Cancer Network
- First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
- Changing Epidemiology of Small-Cell Lung Cancer in the United States Over the Last 30 Years: Analysis of the Surveillance, Epidemiologic, and End Results Database
- Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial
- Topotecan Versus Cyclophosphamide, Doxorubicin, and Vincristine for the Treatment of Recurrent Small-Cell Lung Cancer
- Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data
- Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial
- Randomized Phase III Trial of Amrubicin Versus Topotecan As Second-Line Treatment for Patients With Small-Cell Lung Cancer
- Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial
- Phase III Study of Oral Compared With Intravenous Topotecan As Second-Line Therapy in Small-Cell Lung Cancer